Organization | Ningbo No. 5 Hospital

Ningbo No. 5 Hospital Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Ningbo China (2011)

Organization Overview

First Clinical Trial

2014

NCT02234739

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

Ningbo No.5 Hospital (Ningbo Cancer Hospital) | Ningbo No.5 Hospital(Ningbo Cancer Hospital) | Ningbo People's Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

voriconazole (vfend) (1 trial)

Drugs in Phase 2 Trials (5)

anti-ctla-4/pd-1 expressing egfr-car-t cells (1 trial)

anti-ctla-4/pd-1 expressing muc1-car-t cells (1 trial)

dendritic cells (3 trials)

herincar-pd1 cells (1 trial)

mesothelin car t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Aspergillosis (Phase 4)

Invasive Pulmonary Aspergillosis (Phase 4)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 2)

Pulmonary Aspergillosis (Phase 4)

Stomach Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 6